Management of hyperuricemia in gout: focus on febuxostat

References

• SinghHTorralbaKDTherapeutic challenges in the management of gout in the elderlyGeriatrics200863713182018593209
   PubMed Web of Science ®Google Scholar
• SaagKGChoiHEpidemiology, risk factors, and lifestyle modifications for goutArthritis Res Ther20068Suppl 1S216820041
   PubMed Web of Science ®Google Scholar
• PascualESiveraFWhy is gout so poorly managed?Ann Rheum Dis200766101269127017881662
   PubMed Web of Science ®Google Scholar
• ZhangWDohertyMPascualEfor EULAR Standing Committee for International Clinical Studies Including TherapeuticsEULAR evidence based recommendations for gout – Part I Diagnosis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Ann Rheum Dis200665101301131116707533
   PubMed Web of Science ®Google Scholar
• ZhangWDohertyMBardinTfor EULAR Standing Committee for International Clinical Studies Including TherapeuticEULAR evidence based recommendations for gout – Part II Management: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Ann Rheum Dis200665101312132416707532
   PubMed Web of Science ®Google Scholar
• ArromdeeEMichetCJCrowsonCSO’FallonWMGabrielSEEpidemiology of gout: is the incidence rising?J Rheumatol29112403240612415600
   PubMed Web of Science ®Google Scholar
• WallaceKRiedelAJoseph-RidgeNWortmannRIncreasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care populationJ Rheumatol20043181582158715290739
   PubMed Web of Science ®Google Scholar
• FamAGGout in the elderly. Clinical presentation and treatmentDrugs Aging19981332292439789727
   PubMed Web of Science ®Google Scholar
• Ene-StroescuDGorbienMJGouty arthritis. A primer on late-onset goutGeriatrics2005607243116026179
   PubMed Web of Science ®Google Scholar
• HoskisonKTWortmannRLManagement of gout in older adults: barriers to optimal controlDrugs Aging2007241213617233545
   PubMed Web of Science ®Google Scholar
• De LeonardisFGovoniMColinaMBruschiMTrottaFElderly-onset gout: a reviewRheumatol Int20072811617653719
   PubMed Web of Science ®Google Scholar
• ChoiHKMountDBReginatoAMPathogenesis of goutAnn Intern Med2005143749951616204163
   PubMed Web of Science ®Google Scholar
• EnomotoAKimuraHChairoungduaAShigetaYJutabhaPChaSHMolecular identification of a renal urate anion exchanger that regulates blood urate levelsNature2002417688744745212024214
   PubMed Web of Science ®Google Scholar
• KolzMJohnsonTSannaSMeta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrationsPLoS Genet200956e100050419503597
   PubMed Web of Science ®Google Scholar
• SpiekerLERuschitzkaFTLüscherTFNollGThe management of hyperuricemia and gout in patients with heart failureEur J Heart Fail20024440341012167377
   PubMed Web of Science ®Google Scholar
• BagatinJSardelicSPivacNComparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertensionInt J Clin Pharmacol Res19981873789675624
   PubMedGoogle Scholar
• GurwitzJHKalishSCBohnRLThiazide diuretics and the initiation of anti-gout therapyJ Clin Epidemiol1997509539599291881
   PubMed Web of Science ®Google Scholar
• DunnCJFittonABrogdenRNTorasemide. An update of its pharmacological properties and therapeutic efficacyDrugs1995491211427705212
   PubMed Web of Science ®Google Scholar
• CaspiDLubartEGraffEHabotBYaronMSegalRThe effect of mini-dose aspirin on renal function and uric acid handling in elderly patientsArthritis Rheum200043110310810643705
   PubMed Web of Science ®Google Scholar
• DieppePAInvestigation and management of gout in the young and the elderlyAnn Rheum Dis19915042632662029210
   PubMed Web of Science ®Google Scholar
• PascualETovarJRuizMTThe ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluidAnn Rheum Dis198948129839852559666
   PubMed Web of Science ®Google Scholar
• KanellisJKangD-HFeigDIWortmannRLBeckerMARyanLMAsymptomatic hyperuricemiaCrystal-Induced Artrhopathies: Gout, Pseudogout and Apatite-Associated SyndromesNew YorkTaylor and Francis Group20068485
   Google Scholar
• SchlesingerNDetryMAHollandBKLocal ice therapy during bouts of acute gouty arthritisJ Rheumatol200429233133411838852
   PubMed Web of Science ®Google Scholar
• JanssensHJJanssenMvan de LisdonkEHvan RielPLvan WeelCUse of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trialLancet200837196271854186018514729
   PubMed Web of Science ®Google Scholar
• RubinBRBurtonRNavarraSSmugarSSTershakovecAMEfficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trialArthritis Rheum200450759860614872504
   PubMed Web of Science ®Google Scholar
• SchumacherHRJrBoiceJADaikhDIRandomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritisBMJ200232473521488149212077033
   PubMed Web of Science ®Google Scholar
• ElisafMTsimichodimosVBairaktariESiamopoulosKCEffect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemiaJ Cardiovasc Pharmacol1999341606310413068
   PubMed Web of Science ®Google Scholar
• KaTInokuchiTTsutsumiZTakahashiSMoriwakiYYamamotoTEffects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine basesInt J Clin Pharmacol Ther2006441222616425967
   PubMed Web of Science ®Google Scholar
• GaoXCurhanGFormanJPAscherioAChoiHKVitamin C intake and serum uric acid concentration in menJ Rheumatol20083591853185818464304
   PubMed Web of Science ®Google Scholar
• ChoiHKGaoXCurhanGVitamin C intake and the risk of gout in men: a prospective studyArch Intern Med2009169550250719273781
   PubMedGoogle Scholar
• LevinsonWCohenMSBradyDTo change or not to change: “Sounds like you have a dilemma”Ann Intern Med2001135538639111529714
   PubMed Web of Science ®Google Scholar
• ChoiHKAtkinsonKKarlsonEWWillettWCurhanGPurine-rich foods, dairy and protein intake, and the risk of gout in menN Engl J Med2004350111093110315014182
   PubMed Web of Science ®Google Scholar
• FerrazMBO’BrienBA cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritisJ Rheumatol19952259089148587081
   PubMed Web of Science ®Google Scholar
• Pérez-RuizFCalabozoMPijoanJIHerrero-BeitesAMRuibalAEffect of urate-lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Rheum200244735636012209479
   PubMed Web of Science ®Google Scholar
• SarawateCAPatelPASchumacherHRSerum urate levels and gout flares: analysis from managed care dataJ Clin Rheumatol2006122616516601538
   PubMed Web of Science ®Google Scholar
• ShojiAYamanakaHKamataniNA retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapyArthritis Rheum200451332132515188314
   PubMed Web of Science ®Google Scholar
• YamanakaHTogashiRHakodaMOptimal range of serum urate concentrations to minimize risk of gouty attacks during antihyperuricemic treatmentAdv Exp Med Biol199843113189598023
   PubMed Web of Science ®Google Scholar
• JordanKMCameronJSSnaithMfor British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG)British society for Rheumatology and British Health Professionals in Rheumatology guideling for the management of goutRheumatology (Oxford)20084681372137417522099
   PubMed Web of Science ®Google Scholar
• SutariaSKatbamnaRUnderwoodMEffectiveness of interventions for the treatment of acute and prevention of recurrent gout – a systematic reviewRheumatology (Oxford)200645111422143116632483
   PubMed Web of Science ®Google Scholar
• Pérez-RuizFAlonso-RuizACalabozoMHerrero-BeitesAGarcía-ErauskinGRuiz-LuceaEEfficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic goutAnn Rheum Dis19985795455499849314
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
   PubMed Web of Science ®Google Scholar
• ReindersMKvan RoonENHoutmanPMBrouwersJRJansenTLBiochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patientsClin Rheumatol20072651459146517308859
   PubMed Web of Science ®Google Scholar
• ReindersMKVan RoonENJansenTLThAEfficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinolAnn Rheum Dis2009681515618250112
   PubMed Web of Science ®Google Scholar
• ReindersMKHaagsmaCJansenTLTAA randomized controlled trial with dose escalation on the efficacy and tolerability of allopurinol 300/600 mg/day versus benzbromarone 100–200 mg/day in gout patientsAnn Rheum Dis200968689289718633127
   PubMed Web of Science ®Google Scholar
• DalbethNKumarSStampLGowPDose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with goutJ Rheumatol20063381646165016783857
   PubMed Web of Science ®Google Scholar
• ChungYStockerSLGrahamGGDayROOptimizing therapy with allopurinol: factors limiting hypouricemic efficacyAm J Med Sci2008335321922618344696
   PubMed Web of Science ®Google Scholar
• PanomvanaDSripraditSAngthararakSHigher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney diseaseJ Clin Rheumatol200814161118431090
   PubMed Web of Science ®Google Scholar
• BorstadGCBryantLRAbelMPScroggieDAHarrisMDAllowayJAColchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritisJ Rheumatol200431122429243215570646
   PubMed Web of Science ®Google Scholar
• WortmannRLRecent advances in the management of gout and hyperuricemiaCurrent Opin Rheumatol2005173319324
   Web of Science ®Google Scholar
• ArellanoFSacristánJAAllopurinol hypersensitivity syndrome: a reviewAnn Pharmacother19932733373438453174
   PubMed Web of Science ®Google Scholar
• HandeKRNooneRMStoneWJSevere allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiencyAm J Med198476147566691361
   PubMed Web of Science ®Google Scholar
• CHMP 2008Committee for medicinal products for human use summary of positive opinion for adenuric2122008 URL: http://www.emea.europa.eu/pdfs/human/opinion/Adenuric_8075108en.pdf
   Google Scholar
• CDER 2009Center for Drug Evaluation and Research URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149534.htm
   Google Scholar
• JansenTLReindersMKVan RoonENBrouwersJRBJBenzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence?”Clin Exp Rheumatol200422565115485024
   PubMed Web of Science ®Google Scholar
• LeeMHGrahamGGWilliamsKMDayROA benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Drug Saf200831864366518636784
   PubMed Web of Science ®Google Scholar
• MoolenburghJDReindersMKJansenTLRasburicase treatment in severe tophaceous gout: a novel therapeutic optionClin Rheumatol200625574975216247589
   PubMed Web of Science ®Google Scholar
• VogtBUrate oxidase (rasburicase) for treatment of severe tophaceous goutNephrol Dial Transplant200520243143315673692
   PubMed Web of Science ®Google Scholar
• BeckerMAKisickiJKhosravanRFebuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteersNucleosides Nucleotides Nucleic Acids2004238911111116
   Web of Science ®Google Scholar
• KhosravanRKukulkaMJWuJTJoseph-RidgeNVernilletLThe effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseJ Clin Pharmacol20084891014102418635756
   PubMed Web of Science ®Google Scholar
• KhosravanRGrabowskiBWuJTJoseph-RidgeNVernilletLEffect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsBr J Clin Pharmacol200865335536317953718
   PubMed Web of Science ®Google Scholar
• SchumacherHRJrFebuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with goutExpert Opin Investig Drugs2005147893903
   PubMed Web of Science ®Google Scholar
• HairPIMcCormackPLKeatingGMFebuxostatDrugs200868131865187418729537
   PubMed Web of Science ®Google Scholar
• BruceSPFebuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and goutAnn Pharmacother200640122187219417132810
   PubMed Web of Science ®Google Scholar
• MayerMDKhosravanRVernilletLWuJTJoseph-RidgeNMulfordDJPharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentAm J Ther2005121223415662289
   PubMedGoogle Scholar
• HoshideSTakahashiYIshikawaTPK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairmentNucleosides Nucleotides Nucleic Acids2004238911171118
   Web of Science ®Google Scholar
• KhosravanRGrabowskiBAMayerMDWuJTJoseph-RidgeNVernilletLThe effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseJ Clin Pharmacol20064618810216397288
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutArthritis Rheum200552391692315751090
   PubMed Web of Science ®Google Scholar
• SchumacherHRBeckerMALloydEMacDonaldPALademacherCFebuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety studyRheumatology (Oxford)200948218819419141576
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
   PubMed Web of Science ®Google Scholar
• MorelandLWFebuxostat – treatment for hyperuricemia and gout?N Engl J Med2005353232505250716339099
   PubMed Web of Science ®Google Scholar
• RundlesRWMetzENSilbermanHRAllopurinol in the treatment of goutAnn Intern Med19666422292585322938
   PubMed Web of Science ®Google Scholar
• SchumacherHRJrBeckerMAWortmannRLEffects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trialArthritis Rheum200859111540154818975369
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRMacDonaldPALloydELademacherCClinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with goutJ Rheumatol20093661273128219286847
   PubMed Web of Science ®Google Scholar
• BeckerMSchumacherHRJrEspinozaLA phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with goutPresented at: the Meeting of the American College of RheumatologyOctober 24–29, 2008San Francisco, California URL: http://acr.confex.com/acr/2008/webprogram/Paper3414.html
   Google Scholar
• GaffoALSaagKGFebuxostat: the evidence for its use in the treatment of hyperuricemia and goutCore Evidence200942536
   Google Scholar
• European Medicines Agency (EMEA)Summary of product characteristics 19/05/2009 Adenuric-H-C-777-T-13. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/adenuric/emea-combinedh777en.pdf
   Google Scholar